Early innate events that enable priming of antifungal CD4 T cells are poorly understood. We engineered an attenuated fungal vaccine with a model epitope, EaRFP, to track vaccine immunity to Blastomyces dermatitidis during yeast recognition, antigen presentation, and priming of naive T cells. After subcutaneous injection of the vaccine, monocyte-derived inflammatory dendritic cells (DCs) are the earliest and largest population that associates with yeast, carrying them into the draining lymph nodes. Despite marked association with yeast, these DCs fail to display surface peptide:MHC complexes or prime naive T cells. Instead, the ability to display antigen and prime CD4 T cells resides with lymph node-resident DCs after antigen transfer from immigrant DCs and with skin migratory DCs. Our work reveals the dynamic interplay among distinct DC subsets that prime naive CD4 T cells after yeast are injected in the skin and discloses the cellular elements underlying vaccine-induced immunity to fungi.
INTRODUCTION
An increase in fungal diseases has fueled scientific interest in fungal pathogenesis and antifungal immunity, but a vaccine for any of the human systemic mycoses has never been developed. We genetically engineered an attenuated vaccine against experimental infection with the dimorphic fungus Blastomyces dermatitidis, the agent of blastomycosis. Inhalation of spores into the lung of a mammalian host promotes a phase transition to the pathogenic yeast form (Bradsher, 1988) , which produces pneumonia or disseminated infection, depending on the host's immune status. In a murine model, intratracheal administration of spores or yeast leads to pneumonia with 100% mortality. Subcutaneous (s.c.) administration of the attenuated vaccine protects mice against experimental infection and induces sterilizing immunity (Wü thrich et al., 2000) .
The development of fungal vaccines requires an understanding of the elements that bridge innate and adaptive responses during the generation of antifungal immunity. CD4 + T cells mediate the control and clearance of fungi, with Th1 responses having a requisite role, including in vaccine immunity (Romani, 2008) . During the earliest stages of fungal infection, pattern recognition receptors expressed on cells of the myeloid lineage enable the host to first sense the presence of pathogenic fungi and fungal surfaces (Brown, 2006; Netea et al., 2008) . Myeloid cells, particularly dendritic cells (DCs), bridge innate and adaptive immune response to pathogens across all kingdoms. Because of this, DCs have become a target for novel vaccine development strategies (Steinman, 2008) .
DCs are a heterogeneous population of antigen (Ag)-presenting cells (APCs) that drive immune responses toward inflammatory or regulatory pathways (Banchereau and Steinman, 1998) . Adaptive immunity is regulated and fine-tuned by DCs, depending on the type of Ag and DC subset residing at the site of pathogen entry (Dudziak et al., 2007) . In the skin-draining lymph nodes (LNs), which represent the chief site of T cell priming after s.c. vaccination, there are two major categories of DCs: migratory DCs and LN-resident DCs (Villadangos and Schnorrer, 2007) . Migratory DCs include skin-resident DCs and monocyte-derived inflammatory DCs. Skin DCs are comprised of subsets of dermal DCs (CD103 + and CD103
À
) and Langerhans cells (Kaplan et al., 2008) , whereas monocyte-derived DCs arise when circulating monocytes differentiate into DCs at the site of inflammation (Leó n et al., 2007) .
The roles served by these distinct subsets of DCs in priming T cell responses have been analyzed in response to soluble model Ags, viruses, bacteria, and parasites, but they are less well understood for the fungi. In Leishmania major cutaneous infection models and in systems using model soluble proteins such as EaRFP injected s.c., skin DCs are key players in controlling infection or inducing T cell responses (Itano et al., 2003; Moll et al., 1993) . Skin DCs also regulate hypersensitivity responses (Kaplan et al., 2005 ) by taking up foreign or self-proteins at the site of infection, carrying the cargo to the draining LN, and presenting the Ags to T cells (Heath et al., 2004) . Skin migratory DCs also may cooperate with LN-resident DCs to induce T cell responses by transferring viral Ag to resident DCs (Allan et al., 2006) and, in response to ovalbumin (OVA), allowing resident DCs to trap Ag-specific T cells (Allenspach et al., 2008) while migratory DCs induce proliferation (Allan et al., 2006) . Hence, LN-resident DCs also contribute to presenting Ag in the skindraining LNs (Iezzi et al., 2006; Lee et al., 2009) .
Monocyte-derived DCs have gained interest in priming T cell responses to microbes (Hohl et al., 2009; Serbina et al., 2008) . Monocyte-derived inflammatory DCs were shown to prime Th1 responses in a model of cutaneous Leishmaniasis (Leó n et al., 2007) and to prime Ag-specific CD4 + Tg cells in an experimental model of pulmonary aspergillosis (Hohl et al., 2009) . In Aspergillus infection, CCR2 + Ly6C hi monocyte-derived DCs were necessary for priming T cells in the lung, but not in the spleen, underscoring the differences in how T cells are primed in different tissue compartments. The studies above clarify how distinct DC subsets prime T cells in response to model or nonfungal agents or to fungi that are inhaled into the lung during primary infection. They do not offer insight into the early cellular dynamics that underpin generation of a vaccine-induced immune response to fungi, especially initiated in the skin.
We engineered vaccine yeast to express the model Ag EaRFP (Rudensky et al., 1991) to assess sequential stages during the induction of vaccine immunity to fungi after s.c injection. We show that monocyte-derived inflammatory DCs initially take up the majority of vaccine yeast and traffic them to the draining LNs. A subsequent, smaller wave of vaccine-Ag trafficking to the LN is mediated by skin-derived DCs. Despite a large association of yeast with monocyte-derived DCs, the direct priming of naive Ag-specific CD4 T cells in vivo is governed by LN-resident DCs and skin-derived DCs, whereas monocyte-derived DCs function mainly as carriers of Ag particles to the draining LN.
RESULTS

DC Subsets that Associate with Vaccine Yeast in the Draining LNs
We tracked, analyzed, and characterized the cells that associate with attenuated vaccine yeast in the skin-draining LNs by staining the yeast with the fluorescent cell linker PKH26. Thus, the cells that associate with vaccine yeast in the draining LNs are PKH26 + . To elucidate the kinetics of yeast or yeast-Ag delivery into the draining LNs, mice were vaccinated s.c., and the draining LNs were harvested at serial time points. PKH26 + cells entered the LNs at 24 hr and peaked 2-3 days later (Figure 1 ). Itano et al. (Itano et al., 2003) found that soluble protein injected s.c. entered the draining nodes 30 min later. This rapid entry was due to non-cell-associated delivery of the Ag via the lymphatics. In contrast, yeast PKH26 signal in the node was delayed until 24 hr after vaccination, suggesting that yeast ''particles'' are actively transported by migratory cells rather than by passive movement of soluble fungal Ag into the draining node (Figure 1 ). Since DCs prime naive T cells in the draining LNs, we sought to characterize the DCs that harbor and present yeast Ag(s) at this site. Multiple subsets of DCs have been defined by differences in the expression of surface markers (Ló pez-Bravo and Ardavín, 2008; Villadangos and Schnorrer, 2007) . We used CD11c/ CD11b to identify five potential populations of DCs that contain yeast ( Figure 1B) . By FACS analysis, we found a strong correlation between CD11b
+ APC populations and PKH26. Figure 1C ) to confirm and further characterize the identities of the five populations of yeast-loaded cells near the peak of influx into the LN ($day 3). Population I corresponds to conventional LN-resident DCs, which express high levels of CD11c and MHC class II (MHCII) and include both CD8 + and CD8 À subsets (Villadangos and Schnorrer, 2007) . We used skin-FITC painting, which tracks migratory skin DC populations, to establish that population I is FITC À and confirm that this is the LN-resident DC population ( Figure S1 ). In contrast, populations IV and V are migratory skin DCs. Skin DCs are a heterogeneous population of several subsets of dermal DCs and Langerhans cells, identifiable with DEC205 and Langerin markers (Segura and Villadangos, 2009) . About 20% of cells in populations IV and V displayed these markers ( Figure 1C ). These cells also were FITC + after skin painting ( Figure S1 ), supporting their identity as migratory skin DCs (Allan et al., 2006; Iezzi et al., 2006) . We used two alternate means of tracking yeast associated with DCs to verify the findings with PKH26: (1) vaccine yeast engineered with red fluorescent protein and (2) the cell-permeable dye CFSE. Each method yielded results qualitatively similar to those with PKH26, notably in the distribution of yeast among DC subsets ( Figure S2 ). Due to the sensitivity and stability of PKH26, we used it for the rest of our experiments.
Monocyte-derived inflammatory DCs are blood monocytes that differentiate into DCs upon inflammation. They express a monocyte Ly6C marker and exhibit a DC-like CD11c int/+ phenotype (Leó n et al., 2007; Nakano et al., 2009) . Populations II and III are Ly6C + and >90% CD11b hi , indicating they are monocyte-derived cells ( Figure 1C ). Population II also expresses CD11c, indicating they are likely monocyte-derived DCs. In contrast, population III expresses low or no CD11c and is thus likely to be infiltrating monocytes or macrophages. Overall, our phenotypic analysis showed that yeast associated with three major populations of DCs in the draining LNs of vaccinated mice: LN-resident DCs (population I), monocyte-derived DCs (population II), and skin-derived DCs (populations IV and V). (Figures 2A and 2B ). Skin DC subsets (IV and V) with vaccine yeast appear in the node 1 day after monocyte-derived DCs ( Figure 2B ) and account for $25% of cells associated with vaccine yeast by 48-72 hr after vaccination ( Figure 2A Figure S3 ). Thus, the chief cell populations that associated with vaccine yeast in the draining LNs are monocyte-derived inflammatory DCs, skinderived DCs, and resident conventional DCs. The temporal appearance of yeast with monocyte-and skin-derived DCs before they associate with resident DCs is consistent with the possibility that vaccine Ag is transferred to resident DCs in the LN. At the 72 hr peak of PKH26 + cell influx, the number of yeast-associated APCs is distributed evenly among three or four populations, suggesting that multiple DC subsets participate in the vaccine-induced protective immune response to fungi.
We considered that the distribution of live vaccine yeast among DC subsets could be affected by replicating yeast in the LN. We cultured the LNs of mice 72 hr after vaccination, but found <10 yeast/animal (limit of detection). We also compared the distribution of vaccine yeast among DCs in the LN after vaccination with live or heat-killed yeast, and it was similar ( Figure S4 ). Thus, the distribution likely reflects delivery of yeast into the LN, not replication in the node. We also evaluated whether the appearance of yeast Ag within LN-resident cells required ongoing delivery of yeast after vaccination. Pertussis toxin administered together with the vaccine to block cell migration halted entry of yeast into the LN ( Figure S5 ). In contrast, when toxin was given 24 hr after vaccination, yeast still appeared in all of the DC subsets, including LN-resident DCs at 72 hr. These results suggest that cells from the vaccine site deliver yeast into the node and may transfer them to LN-resident DCs.
Alterations of Vaccine Delivery into the LNs of CCR2
À/À , CCR7
À/À , and CD11cDTR Mice
We concluded above that monocyte-derived DCs and skinderived DCs are potential migratory populations that ferry vaccine yeast into the LN for possible Ag transfer to resident conventional DCs ( Figure 1B 
DC Subsets that Process and Display Vaccine Yeast Ag in the Draining LNs
We observed that skin-derived DCs, monocyte-derived DCs, and LN-resident DCs contain vaccine yeast by PKH26 + staining, but the Ag-processing capability of these cells was not addressed. We used YAe antibody to detect Ea peptide displayed by MHCII (Itano et al., 2003) , in conjunction with vaccine Figure 4D) , similar to what has been reported (Itano et al., 2003) . In contrast, the most abundant display of Ea:MHCII in EamCherry yeast-vaccinated animals occurs within the LNresident conventional DCs, with surprisingly few YAe + cells in the monocyte-derived DC and monocyte/macrophage gates ( Figure 4D ). This finding implies that monocyte-derived cells carry yeast into the LN, but may play a limited role in directly displaying yeast Ag to naive T cells. Because Ea:MHCII display is necessary but not sufficient for Ag presentation to naive T cells, we sought to identify the DCs capable of both displaying yeast Ag and priming naive Ag-specific T cells in the LN.
Naive TEa T Cells Report Fungal Ag Processing and Presentation in the Draining LNs
Using naive TEa Tg T cells specific for Ea:MHCII complexes (Murphy et al., 1992; Rudensky et al., 1991) , we determined how the display of fungal Ea-Ag in the draining nodes, as detected by the YAe antibody, correlates with the priming of naive T cells. We found above that CD11b + cells in the LN associate with vaccine yeast ( Figure 1B ) and display yeast-derived Ea-Ag ( Figure 4B ). We therefore collected CD11b Figure 5B ). Naive TEa cells expanded 5-to 8-fold more in mice vaccinated with EamCherry compared to these control groups ( Figure 5C ). Soluble Ag administered s.c. enters the LN in two waves, at 30 min and again at $14 hr, with corresponding early T cell priming (Itano et al., 2003) . We observed that vaccine yeast are dynamically distributed among APC populations in the draining LNs of mice over 7 days after vaccine administration. Here, we analyzed how the kinetics of vaccine Ag delivery into the draining nodes correlates with the kinetics of priming naive T cells at this site. After adoptive transfer of TEa cells, their activation and proliferation was monitored for 12 days in response to vaccination with EamCherry or control yeast. TEa cells initially proliferated at $72 hr in response to EamCherry yeast, as measured by their loss of CFSE ( Figure 5D ). Analysis of other T cell activation markers, such as surface CD25, CD44, or CD69, showed evidence of TEa activation about 24-36 hr earlier (data not shown). Thus, priming of naive T cells by vaccine yeast correlates closely with the initial appearance of PKH26 + signal in the draining LNs of vaccinated mice (Figure 1 ). The lack of evidence of T cell priming before $32 hr in response to vaccine yeast supports the idea that fungal Ag is actively ferried by cells into the draining LN and does not enter by passive diffusion through the lymphatics (Iezzi et al., 2006; Itano et al., 2003 
Cell Host & Microbe
DC Subsets Cooperate to Prime Antifungal T Cells
whether any or all of these DC subsets may be responsible for priming protective T cells in this model of immunization against fungi. Based on the kinetics of T cell priming in vivo, which showed initial T cell expansion at 72 hr in response to EamCherry yeast ( Figures 5C and 5D ), we collected and functionally analyzed in vivo loaded APCs from the draining LNs 3 days after vaccination. The cells were sorted by FACS according to gates that correspond to the different DC subsets ( Figure 6A ). Four populations were sorted from total LN cells: resident DCs (population I), monocyte-derived inflammatory DCs (II), monocytes/macrophages (III) (as a negative control), and skin-derived dermal and Langerhans DCs (IV) ( Figure 6A ). Populations from mice vaccinated with soluble EaRFP, EamCherry yeast, or TR20 control yeast were sorted in parallel. TEa cells were cocultured with sorted cells ex vivo for 72 hr and analyzed for the expression of activation markers. In the EamCherry yeast vaccine group, LN-resident DCs activated the TEa cells, as defined by their increased expression of surface CD44 and CD69 when compared to the TR20 control group; no other sorted populations from the EamCherry group activated the TEa cells ( Figure 6B ). In the soluble EaRFP group, skin DCs activated the TEa cells as described (Itano et al., 2003) , although monocyte-derived DCs and LN-resident DCs were also capable of activating the cells in this ex vivo assay. We were surprised that skin DCs (population IV in Figure 6A ) did not prime TEa cells in EamCherry-vaccinated mice, since the fungal vaccine is most effective when injected s.c. (Wü thrich et al., 2000) . One possibility is that skin DCs were diluted by other cell types, since population IV is sorted from total LN cells. We observed in Figure 1C that populations IV and V are heterogeneous, and only a minor proportion of them are DEC205 + skin DCs ($20% of the PKH26 + population). This raised the possibility that the lack of T cell activation with this population was due to a nonoptimal ratio of DCs to TEa cells in vitro. To address this, we sorted DEC205 + cells in vaccinated mice to enrich skin DCs ( Figure 6C) , and in parallel, we sorted Ly6C + monocytes as a control, which did not prime TEa cells in the EamCherry group ( Figure 6B ). We obtained 10-fold fewer cells by sorting 
DEC205
+ cells compared to sorting population IV in Figure 6A 
Analysis of T Cell Priming In Vivo Unveils Collaborative, Indispensable Roles of DC Subsets
Ex vivo assays do not necessarily portray the functional behavior of APCs in vivo, where distinct DC subsets may collaborate to prime naive T cells (Allenspach et al., 2008) . Hence, we studied the in vivo role of distinct DC subsets in priming naive T cells in response to vaccination. We utilized CCR2 À/À , CCR7 À/À , and CD11cDTR mice ( Figures 7A-7C ). We adoptively transferred naive TEa cells into these mice and monitored T cell activation after vaccination with EamCherry or TR20 control yeast. Our sort data above revealed that LN-resident DCs and skin DCs loaded with Ag in vivo can prime naive T cells ex vivo ( Figure 6 ). The role of these DC subsets in in vivo priming was confirmed in CCR7 À/À and CD11cDTR mice ( Figures 7A and 7C ). CCR7
À/À mice, in which migration of skin DCs is impaired, showed sharply reduced priming of naive TEa cells despite our earlier finding that skin DCs were a minor (<20%) yeast-associated population in the draining LNs ( Figure 1B ). Nearly 69% of naive TEa cells were CFSE lo and primed in wild-type mice vaccinated with EamCherry yeast, whereas 22% of the cells were primed in CCR7 À/À mice ( Figure 7A ). Impairment in TEa priming was even more striking in CD11cDTR mice, which lack conventional LN-resident DCs and where the absence of CD11c hi cells virtually abrogated TEa cell proliferation ( Figure 7A) .
Similarly, the priming of TEa cells was partially impaired in CCR2 À/À mice; proliferation of TEa cells in these mice reached $28% of the maximal response, as compared to 46% in wild-type mice ( Figure 7B ). Hence, although monocyte-derived inflammatory DCs are the least efficient subset in displaying Ea:MHCII after Ag loading in vivo, and our ex vivo analysis of sorted monocyte-derived inflammatory DCs demonstrated that they are incapable of priming TEa cells in vitro, these DCs have a requisite role in the priming of antifungal T cells in vivo in response to vaccination. This is perhaps not surprising, because monocyte-derived DCs are the first to infiltrate the LNs with vaccine yeast after immunization, and this population contains the majority of Ag-loaded cells ( Figure 1B) . Thus, while ex vivo analysis pointed to the functional role of two of the three DC subsets-skin DCs and LN DCs, but not monocyte-derived DCs-in priming TEa cells, in vivo studies establish that the various DC subsets mediate distinct, collaborative, and indispensable roles in priming T cells in response to vaccine.
DISCUSSION
We provide here a comprehensive picture of the earliest stages in the generation of vaccine immunity to a systemic fungal infection. Because DCs are essential in understanding how vaccine immunity is generated (Steinman, 2008) , we focused on elucidating their role in our model. We found that multiple DC subsets collaborate to prime naive Ag-specific CD4 T cells and that the different subsets mediate distinct functions. Monocyte-derived inflammatory DCs mainly transport vaccine yeast Ag into the LN, whereas LN-resident DCs and, to a lesser extent, migrating skin DCs directly prime naive T cells. Our work reveals an intricate interplay between DC subsets during the generation of vaccine immunity to fungi.
Monocyte-derived inflammatory DCs are the earliest and largest cell population that associates with vaccine yeast in the LN. We identified monocyte-derived DCs by their Ly6C hi CD11c int phenotype (Leó n and Ardavín, 2008; Nakano et al., 2009 ). These cells were not detected in naive mice, and their numbers increased sharply after vaccination, supporting their characterization as inflammatory cells. In CCR2 À/À mice, their recruitment into the draining LN was curtailed, and the delivery of vaccine yeast was also reduced. While these DCs played a key role in early recognition, uptake, and trafficking of yeast into the LN, they did not efficiently process and present Ag or prime naive T cells. For such analyses, we exploited the TEa system. Vaccine yeast expressing EaRFP were used to track yeast-derived Ea:MHCII complexes on APCs with YAe mAb and monitor priming of naive Ea-specific ''antifungal'' TEa cells. Monocyte-derived DCs had little processed Ea on their surfaces. In vaccinated mice, these cells were unable to prime naive TEa cells ex vivo.
This discrete role of monocyte-derived DCs in trafficking vaccine yeast to the draining node contrasts with their broader functions in other eukaryotic models. In a L. major cutaneous infection model, Leó n et al. (Leó n et al., 2007) detected two monocyte-derived inflammatory DC populations: LN monocyte-derived DCs (LN mo-DCs) are an immature Ly6C hi population and dermal monocyte-derived DCs (dermal mo-DCs) are a more mature Ly6 int population. The dermal mo-DCs were found to be the principal population expressing L. major LACK Ag peptide and activating Ag-specific T cells ex vivo. In our system, the inflammatory DC is phenotypically most similar to LN mo-DCs (Ly6C hi CD11b hi CD11c int MHCII lo ) described by Leó n et al. (Leó n et al., 2007) . Those cells are purportedly monocytes that enter the LN directly from the blood and differentiate into DCs. There, DCs would be located along high endothelial venules and sample soluble Ags that enter via the lymph. The monocyte-derived inflammatory DCs in our model must be different. They are the first cells to associate with yeast in the LN (24 hr after vaccination). However, these monocyte-derived DCs don't acquire PKH26 + yeast Ag via the lymph. Soluble Ag typically enters the node by 30 min after injection into the skin; DCs that ferry Ag enter later, by around 14 hr after injection (Iezzi et al., 2006; Itano et al., 2003) . In mice vaccinated with yeast, we first detected PKH + signal in the node at 24 hr; therefore, it was likely ferried by DCs. After fungal vaccine, proliferation of naive Ea-specific TEa cells in vivo was delayed until 72 hr, also consistent with cell transport of Ag into the node. Third, impaired monocyte migration in CCR2 À/À mice delayed the kinetics and amount of PKH26 + signal in the draining LN, demonstrating that these monocyte-derived DCs transport yeast into the node from the site of vaccination rather than sampling soluble, cell-free Ag that arrives via the lymph.
The other subset of monocyte-derived inflammatory DCs in the L. major model were dermal mo-DCs (Ly6C lo , CD11b int , CD11c int MHCII hi ) (Leó n et al., 2007) . Neither does our inflammatory DC match that phenotype. Our cells may be an early phenotype of the dermal mo-DCs, since that subset was described at 4 weeks after infection with L. major. Our model instead focused on the initial stages of vaccination at 3 days postinjection. Thus, yeast-associated monocyte-derived DCs are neither dermal mo-DC nor LN mo-DCs reported by Leó n et al. (Leó n et al., 2007) , but likely another monocyte population that arrives at the skin, quickly picks up vaccine yeast, differentiates into CD11b + DCs, and transports Ag into the LN. Differences between the two studies may be due to the differences in timing of analysis or burden of Ag at those points during infection and especially the differing nature of these eukaryotic pathogens. The Ly6C hi monocyte-derived DC subset in our model is similar in phenotype and kinetics to inflammatory monocytederived CD11b + DCs in models of pulmonary aspergillosis (Hohl et al., 2009 ) and cryptococcosis (Osterholzer et al., 2009 ). Hohl et al. reported that Ly6C hi CD11b + CD11c + DCs harbored conidia in the lung 2 days postinfection. These DCs required CCR2 for recruitment into the lung and draining LNs where they induced Th1 differentiation of naive Aspergillusspecific Tg T cells. We also saw that loss of CCR2 delayed the delivery of vaccine yeast into the draining LNs and reduced the number of APCs associated with yeast. In contrast, however, we found that loss of CCR2 only partially impaired priming of naive Ag-specific T cells. The Aspergillus work did not address how monocyte-derived DCs contribute to lung T cell priming, that is, whether the DCs solely transported Ag to the node, primed T cells, or both. Nevertheless, the precise function(s) of monocyte-derived DCs were shown to differ with the tissue site. DCs were essential in priming T cells in the lung, but dispensable for systemic priming in the spleen.
By using YAe antibody to detect Ag display, we went beyond the detection of cell Ag load by PKH26 signal and monitored the ability of distinct DC subsets to display yeast-derived peptide on their surfaces. Importantly, resident DCs displayed more surface peptide than migratory DC subsets. In CCR2 À/À and CCR7 (Eidsmo et al., 2009 ). Based on YAe staining and Ag display, we postulated that mainly skin DCs, after soluble EaRFP vaccination, and LNresident DCs, after vaccine yeast administration, would prime naive T cells. Our ex vivo T cell assays with sorted cells confirmed the YAe staining results and established that in vivo loaded LNresident DCs and, to a lesser extent, migratory skin-derived DCs primed naive T cells. However, previous studies in an OVA-OT II system showed that migratory and LN-resident DCs could prime T cells ex vivo independently of each other, but in vivo priming required the cooperation of both subsets (Allenspach et al., 2008) . In keeping with that study, we observed reduced priming of naive T cells in CD11cDTR mice (lack LN-resident DCs [CD11c hi cells]) (Bennett and Clausen, 2007) and CCR7 À/À mice (impaired entry into the LN of migratory DCs) (Jang et al., 2006; Ohl et al., 2004) . In CD11cDTR mice, T cells were not primed in vivo; in CCR7
À/À mice, T cell priming was reduced $3-fold. Any residual response in CCR7 À/À mice might be due to monocyte-derived DCs that compensated for skin (likely dermal) DCs as the migratory subset. Although monocyte-derived DCs are not efficient in priming T cells directly, they likely transfer Ag from the skin to LN-resident cells, thereby preserving T cell priming in CCR7 À/À mice. Our CCR7 À/À results contrast with those in CCR2 À/À mice, where the defect in T cell priming was less pronounced. There, the putative role of CCR2 + monocyte-derived DCs likely could be rescued partially by other populations in the skin, likely the dermal DCs. This finding reinforces the conclusion by Hohl et al. (Hohl et al., 2009 ) that tissue site influences the role of monocyte-derived DCs in response to fungi. Our study offers new insight into how these DCs help prime T cells to yeast injected into the skin and promote vaccine immunity to fungi. LN-resident DCs were indispensable in the generation of vaccine immunity to fungi in our model. This DC subset made up the bulk of surface Ag-displaying cells in the draining LNs of vaccinated mice, and they primed naive TEa T cells ex vivo and were required in priming them in vivo. LN-resident DCs also have a seminal role in inducing T cell immunity against Leishmania and HSV-1 (Allan et al., 2006; Iezzi et al., 2006) . In HSV-1 infection, the route of inoculation determines which DC subset induces the activation of T cells (Lee et al., 2009 ). Dermal DCs prime T cells when HSV is introduced via the mucosa, whereas LN-resident DCs show a more prominent role after needle inoculation (Lee et al., 2009) . One explanation for the , 2000) . Most studies of the role of DCs in priming antimicrobial T cell responses have emphasized the seminal role of a distinct DC subset, according to the pathogen or the site of entry or injection. In contrast, our study reveals the interplay among multiple distinct subsets. Whereas both monocyte-derived and dermal DCs ferry vaccine yeast into the draining LN, neither subset fully compensates for the other in chemokine receptor-deficient mice, and the priming of CD4 T cells was impaired in both CCR2
À/À and CCR7 À/À mice. CCR7 À/À mice showed a striking defect in T cell priming, likely due to the multiple functions of dermal DCs: trafficking and transferring of Ag to resident DCs, as well as priming of T cells. We did not formally show Ag transfer to resident DCs, but the findings that Ag must be ferried into the node by cell migrants and that blocking cell migration by toxin 24 hr after vaccination failed to curtail the uptake of Ag in resident DCs are most consistent with that mechanism.
Our study exploited a model Ag to clarify sequential steps in initiating Ag-specific antifungal immunity, but it is valid to ask whether the response to this model Ag accurately portrays vaccine immunity to fungi. We recently used CD4 T cells from a newly created Blastomyces-specific TCR Tg mouse, which confirmed our results here with TEa cells (our unpublished data). Overall, our results typify the cooperation of multiple DC subsets needed to prime CD4 T cells in response to the model Ag OVA (Allenspach et al., 2008) . Upon s.c. injection of live attenuated yeast, the generation of vaccine immunity likewise demands the dynamic and functional collaboration of both migratory and resident DC subsets.
EXPERIMENTAL PROCEDURES Mice
Wild-type C57BL/6 mice were obtained from the National Cancer Institute (Bethesda, MD). TEa TCR transgenic mice were provided by A.Y. Rudensky at the Howard Hughes Medical Institute, University of Washington (Itano et al., 2003) . CCR2 À/À (stock #04999), CCR7 À/À (stock #05794), and CD11cDTR/GFP mice (stock #04509) were obtained from Jackson Laboratory. CD11c hi cells were depleted from CD11cDTR/GFP mice by one intraperitoneal injection of 100 ng diphtheria toxin per animal. Mice were 10-12 weeks of age at the time of our experiments. Experimental procedures and housing were performed according to the guidelines of the University of Wisconsin Animal Care Committee, who approved this work.
Fungi
Blastomyces strain 55 is an attenuated yeast created from the isogenic virulent strain American Type Culture Collection (ATCC) 26199 (Manassas, VA) by targeting and deleting the gene encoding BAD1 (Brandhorst et al., 1999) . EamCherry yeast was engineered as described in Supplemental Experimental Procedures. Strain TR20 served as a control in some experiments. All fungal isolates were maintained in the yeast form at 39 C on Middlebrook 7H10 agar slants (BD Diagnostics; Franklin Lakes, NJ).
Staining of Vaccine Yeast and Subcutaneous Immunization
Yeast were labeled with the red fluorescent linker PKH26GL (Sigma, St. Louis) in Diluent C (Sigma) at a concentration of 2 3 10 6 yeast/ml PKH26 for 5 min at room temperature. An equal volume of FBS (Cellgro; Mediatech, Inc.; Manassas, VA) was added to bind excess PKH26 for 1 min, followed by a single wash with RPMI medium supplemented with 10% FBS and then by two washes with PBS. Yeast were labeled with CFSE using the manufacturer's instructions (Molecular Probes; Eugene, OR) for lymphocytes and yielded strong fluorescent intensity. For vaccination, PKH-labeled yeast were suspended at 1 3 10 7 cells/ml in PBS, and two injections were given s.c. Each injection site received 5 3 10 6 yeast in 500 ml. Approximately 100-200 mg EaRFP in PBS was administered s.c. as for vaccine yeast. The EaRFP (Ea plus DsRed) protein was expressed in recombinant form in Escherichia coli and purified as described by Itano et al. (2003) . DC migration into the draining LN was blocked by adding 500 ng pertussis toxin (Sigma-Aldrich, St. Louis) to vaccine yeast during s.c. injection. To inhibit DC migration following vaccination, 300 ng pertussis toxin was given intravenously (i.v.) 24 hr after vaccine yeast were injected.
T Cell Preparation and Adoptive Transfers
Naive CD4 + T cells were harvested from the spleen and LNs of naive TEa mice.
Splenocytes and LN single-cell suspensions were enriched on CD4 magnetic beads (IMag, BD Bioscience). T cells were enriched per the manufacturer's instructions. T cells were cocultured with various concentrations of DCs at 3 3 10 5 T cells/well. For adoptive transfers, single-cell suspensions of whole splenocytes of naive TEa Thy1.1 + mice were stained with CFSE (Molecular Probes) before transfer, per the manufacturer's instructions. CFSE-labeled TEa cells were transferred i.v. at 10 6 or 2 3 10 6 per animal to obtain from $10 5 to 2 3 10 5 CD4 + T cells, respectively, since $10% of total splenocytes are CD4 + TEa T cells. A day after transfer, mice were vaccinated with 10 6 yeast s.c., and brachial and inguinal LNs were harvested 3 days later.
FACS Analysis and Cell Sorting
These were performed as described in Supplemental Experimental Procedures.
Statistics
Differences in the number of cells were analyzed using Wilcoxon rank test for nonparametric data or a t test if data were normally distributed. A Bonferroni adjustment was used to correct for multiple tests. A value of p < 0.05 is considered significant.
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